Celldex Therapeutics (CLDX) revenue breakdown
By product, Contracts and grants is the largest at 94% of fiscal 2025 revenue, growing -12% a year over 9 years.
Revenue by product
Fiscal years, as Celldex Therapeutics reports them in its 10-K filings; fiscal 2025 total $2M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Contracts and grants | $5M | $10M | $6M | $3M | $5M | $5M | $2M | $7M | $7M | $1M | 94% |
| Product development and licensing agreements | $2M | $3M | $3M | $473,000 | $2M | $31,000 | $56,000 | $278,000 | $13,000 | $97,000 | 6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CLDX.
Open CLDX in InvestinglyQuestions
Where does Celldex Therapeutics make its money?
In fiscal 2025, by product: Contracts and grants $1M, Product development and licensing agreements $97,000.
From Celldex Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.